AUS
NZ
UK
CA
USA
IND
Healthcare
GSK (LSE:GSK) Shares Rise Amid Asia Regulatory Moves and 35Pharma Deal
February 27, 2026 12:01 PM GMT| By Vivek SinghGSK updates pipeline with Asia regulatory approvals and 35Pharma acquisition, strengthening growth prospects ahead of first-quarter results.
AstraZeneca’s Oncology Drive Gains Momentum on LSE
February 27, 2026 10:27 AM GMT| By Vivek SinghAstraZeneca advances oncology and respiratory therapies with new approvals and filings, strengthening its footprint across the LSE & FTSE stock market and reinforcing its long-term healthcare growth strategy.
GSK Share Price Swings: Is Value Emerging Now?
February 27, 2026 09:55 AM GMT| By Vivek SinghAn in-depth look at GSK’s valuation after recent volatility, exploring share price trends, growth outlook, pipeline risks, and its position within the UK equity market.
GSK Strengthens Respiratory & Kidney Pipeline With Key Deals
February 26, 2026 03:21 PM GMT| By Vivek SinghGSK expands respiratory and kidney pipeline with new acquisitions and gene silencing deals in Canada and China.
AstraZeneca Gains Fresh Oncology Edge With Key Approvals
February 26, 2026 03:16 PM GMT| By Vivek SinghAstraZeneca advances its oncology leadership as CALQUENCE and ENHERTU achieve new regulatory milestones, reinforcing its strategy across blood cancers and HER2 positive breast cancer markets.
FTSE Momentum: GSK Ignites UK Pharma Dealmaking
February 25, 2026 11:10 AM GMT| By Team Kalkine MediaA strategic pharmaceutical partnership strengthens innovation, supports UK healthcare leadership, and reinforces long‑term confidence in the evolving life sciences ecosystem.
Is FTSE 100 Reassessing GSK?
February 25, 2026 10:32 AM GMT| By Vivek SinghPharmaceutical heavyweight GSK remains central to FTSE discourse as valuation frameworks and sector themes shape its standing within the flagship UK benchmark.
AstraZeneca’s Place Within FTSE 350 Landscape
February 25, 2026 10:31 AM GMT| By Vivek SinghAstraZeneca’s role within the FTSE 100 reflects the strength of the UK pharmaceutical sector and its influence on benchmark composition and market discussions.
Is FTSE AIM 100 Index Watching HUTCHMED?
February 24, 2026 06:45 PM GMT| By Vivek SinghOncology focused HUTCHMED remains a visible constituent of the FTSE AIM benchmark, reflecting its research platform and commercial presence within the UK equity landscape.
AstraZeneca Advances Oncology Portfolio with Key Regulatory Milestones
February 24, 2026 04:55 PM GMT| By Vivek SinghExplore AstraZeneca’s latest oncology approvals and regulatory milestones, enhancing its presence in leukemia, breast cancer, and rare lymphoma markets.
Oxford BioMedica (LSE:OXB) Shares Drop Ahead of EQT Deadline
February 24, 2026 12:10 PM GMT| By Vivek SinghExplore Oxford BioMedica's trading update, revenue growth, and EQT bid overhang, with insights on FTSE 100 shares price and UK stock market trends.
FTSE Spotlight: Convatec’s Market Momentum Ignites Sector Confidence
February 24, 2026 11:00 AM GMT| By Vivek SinghConvatec’s renewed outlook reflects a broader shift in healthcare sentiment, reinforcing the sector’s role as a stable, innovative and strategically essential force within the UK market ecosystem.
Cizzle Biotech Royalty Deal Fuels US Launch Momentum
February 23, 2026 11:09 AM GMT| By Vivek SinghCizzle Biotechnology Holdings PLC (LSE:CIZ) strengthens its US expansion plans with extended royalty arrangements and progress toward commercial launch of its lung cancer biomarker test, reinforcing its diagnostics strategy and market presence.
AIM Market Focus on SkinBioTherapeutics Governance Review
February 20, 2026 08:45 AM GMT| By Vivek SinghAn AIM biotech enters a governance review phase, strengthening transparency, reshaping market confidence, and reflecting the growing importance of accountability across UK equity markets.
GSK Share Momentum Sparks Valuation Debate
February 20, 2026 04:13 AM GMT| By Vivek SinghGSK share momentum sparks valuation discussion as market sentiment focuses on pipeline strength, regulatory developments, and long-term outlook within the LSE & FTSE stock market and broader pharmaceutical sector.
Advanced Medical Solutions Group and FTSE AIM 100 Index dynamics
February 19, 2026 10:48 AM GMT| By Vivek SinghAdvanced Medical Solutions Group operates within global surgical and woundcare markets while maintaining presence in the FTSE AIM 100 Index amid evolving UK equity conditions.
GSK positioned within FTSE amid pharma momentum
February 19, 2026 09:47 AM GMT| By Vivek SinghGSK’s recent market strength reflects portfolio depth, vaccine momentum, and sector dynamics, framed within its established position among major UK pharmaceutical groups.
Trellus Health Gains Momentum on J&J Programme Extension
February 18, 2026 07:03 PM GMT| By Vivek SinghTrellus Health strengthens its healthcare strategy through a Johnson & Johnson programme extension, advancing digital care solutions and clinical trial services while expanding its presence across immunology and inflammation treatment pathways.
Bioventix draws attention within the FTSE market landscape
February 18, 2026 08:08 AM GMT| By Vivek SinghBiotechnology supplier within the UK AIM segment combines diagnostic antibody expertise with an established dividend record in the broader equity market.
Uniphar within UK FTSE healthcare landscape
February 18, 2026 08:06 AM GMT| By Vivek SinghUniphar’s role within the FTSE 350 highlights its diversified healthcare services model across Ireland, the UK and Benelux, drawing market attention to operational structure and sector context.
